Center for Early Detection and Interception of Gynecologic Tumors

Centers for Early Detection and Interception


The Center for Early Detection and Interception of Gynecologic Tumors is part of Dana-Farber’s Centers for Early Detection and Interception, a new multidisciplinary clinical and research program for individuals who are at increased risk of developing cancer.

Talk with one of our experts to evaluate if the Centers for Early Detection and Interception is the right next step for you or your patient's care.

The Center for Early Detection and Interception of Gynecologic Tumors aims to increase early detection of gynecologic cancers and actively monitor people at elevated risk of developing gynecological cancers, so that interventions can be offered at the right time. 

Understanding Your Risk

Gynecologic tumors include ovarian, endometrial/uterine, cervical, vulvar, vaginal, and fallopian tube cancers. Cancer can occur for a variety of reasons, but some people have a higher risk because of genetics, family history, or the presence of precursor lesions. Our team can help you assess if you are at elevated risk and would benefit from being seen by a provider.

What Are Precursor Conditions?

Precursor conditions are early phases of diseases that may develop into cancers. Precursors of gynecologic tumors include endometrial intraepithelial neoplasia (EIN).

What Are Hereditary Gynecologic Cancer Syndromes?

Hereditary syndromes that increase the chances of gynecological cancers include (but are not limited to) Lynch syndrome, Peutz-Jeghers syndrome, Cowden syndrome, and those with pathogenic genetic mutations in genes BRCA1, BRCA2, or other non-BRCA high-risk mutations such as PALB2, BARD1, and TP53. We also include patients with a family history of ovarian cancer or certain patterns of uterine cancers in a high-risk group, even without a known genetic mutation.

Our Services

Our multidisciplinary approach to care ensures patients benefit from the care of gynecologist-oncologists, surgeons, and advanced practice providers who are experts in gynecologic cancer and the latest early detection and interception strategies for individuals at elevated risk. Our clinicians provide:

  • Personalized risk assessment and surveillance recommendations informed by current literature
  • Risk-reduction strategies including contraceptive counseling, lifestyle modifications, and risk-reducing surgery consultation
  • Screening endometrial biopsies for those who are at elevated risk for uterine cancer and meet the screening criteria

Additionally, we offer genetic counseling, individualized risk assessment, access to clinical research studies, social support, and more.

Advanced Diagnostics

Our Center offers advanced diagnostic and sequencing technology to diagnose and assess each patient's condition. 

Our specialists provide patients with individualized assessments of their risk of progression to gynecologic cancers and ongoing monitoring. This may include certain types of screening with imaging or biopsies, surgical interventions, participation in clinical trials of novel therapies, and lifestyle changes that reduce the risk of developing cancer.

Condition-Specific Expertise

Patients meet with a gynecologist-oncologist, surgeon-scientist or advanced practice provider with an in-depth knowledge of risk factors and screening methods for gynecologic cancers. The provider will conduct an individualized assessment of the patient’s risk for developing cancer and work with the patient to identify the best management option.

Providers will discuss surgical options, hormonal therapy recommendations, and screening procedures such as PAP smears, endometrial biopsies, screening ultrasounds, and other imaging.

Genetic Counseling

Patients may be evaluated by an experienced genetic counselor to discuss their personal and family health history, cancer risk, additional cancer screening recommendations, and potential strategies to lower the risk of progression. 

Additionally, if a patient being actively followed in our Genetics and Prevention Clinic develops a precursor condition, they will have access to our providers in the Center for Early Detection and Interception of Gynecologic Tumors.

Clinical Trial Opportunities

Our team is committed to advancing research of early detection and interception strategies. For patients today, this means access to clinical trials of new tests and therapies, as well as the opportunity to participate in biobanking studies.

Social Support

Patient navigators, psychologists, and social workers are available by referral to offer patients resources and support.

Meet Our Team


Tara Berman, MD, MS
Division of Gynecologic Oncology, Dana-Farber Cancer Institute
Faculty, Harvard Medical School

Kevin Elias, MD
Director, Gynecologic Oncology Laboratory, Brigham and Women's Hospital

Advanced Practice Providers

Arianna Maselli, MPAS, PA-C, Physician Assistant

Genetic Counselors

Karina Franca, MS, CGC
Liz Kearns, MS, CGC